You are here

NDA for Anti-Insomnia Candidate Filed With FDA

MARLBOROUGH, Mass., April 2 /PRNewswire-FirstCall/-- Sepracor Inc. (Nasdaq: SEPR - News) today announced that the U.S. Food and Drug Administration (FDA) has filed Sepracor's New Drug Application (NDA) for ESTORRA(TM) brand eszopiclone 2 mg and 3 mg tablets for the treatment of transient and chronic insomnia. ESTORRA was studied in the 3 mg dosage strength for adults and in the 2 mg dosage strength for treatment of the elderly population. Sepracor submitted the ESTORRA NDA to the FDA on January 31, 2003.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs